Figure 3
Promising combined H3R antagonist, G9a- and Spindlin1-inhibitor activity of A366 for pharmacotherapy of Prader–Willi syndrome (PWS).
Figure 3 | Scientific Reports
Promising combined H3R antagonist, G9a- and Spindlin1-inhibitor activity of A366 for pharmacotherapy of Prader–Willi syndrome (PWS).
